Recordati

REC

IT0003828271

Pharmaceuticals

Market Closed - Borsa Italiana Other stock markets 11:45:00 2026-02-17 am EST			5-day change	1st Jan Change
47.34 ^EUR	0.00%		-1.00%	-2.47%

Feb. 17	Italy's Recordati targets 2026 core profit increase	RE
Feb. 17	Recordati Posts Strong Results with Rising Profits and Revenues	AN

Recordati Buys Back 52,000 Own Shares for Over EUR2 Million

Published on 01/05/2026 at 12:35 pm EST

Alliance News - Translated by Marketscreener - See original

RECORDATI

0.00%

(Alliance News) - Recordati Spa announced on Monday that it had repurchased 51,977 of its own ordinary shares between December 22 and December 30.

The shares were acquired at an average unit price of EUR48.5540, for a total value of EUR2.5 million.

Following these purchases, the company now holds a total of 4.8 million treasury shares, representing approximately 2.3% of its share capital.

On Monday, Recordati's stock closed down 1.9% at EUR47.36 per share.

By Claudia Cavaliere, Alliance News reporter

Comments and questions to redazione@alliancenews.com

Latest news about Recordati

Feb. 17	Italy's Recordati targets 2026 core profit increase	RE
Feb. 17	Recordati Posts Strong Results with Rising Profits and Revenues	AN
Feb. 17	Recordati FY EBITDA EUR 991.1 mln	RE
Feb. 17	Mib Recovers Below 45,600; Inwit and Italgas Lead the Way	AN
Feb. 17	Bearish Outlook for the Second Day of the Week	AN
Feb. 17	Italy - Factors to watch on February 17	RE
Feb. 16	Recordati Acquires 64,038 Treasury Shares for Over EUR3 Million	AN
Feb. 16	Galderma Group AG Announces the Appointment of Luigi La Corte as Chief Financial Officer, Effective May 1, 2026	CI
Feb. 16	Dermatology Company Galderma Group Names New CFO	MT
Feb. 13	Diary - Europe's STOXX 600 Corporate Earnings Week Ahead	RE
Feb. 13	DIARY - Italy to March 31	RE
Feb. 12	Barclays Upgrades Recordati to Equalweight Rating	MT
Feb. 12	Italy - Factors to watch on February 12	RE
Feb. 11	TIM and Italgas Push Higher, but the Mib Remains Bearish	AN
Feb. 10	Recordati Purchases Own Shares Worth Approximately EUR 3 Million	AN

Recordati S.p.A. specializes in the research, development, production and marketing of pharmaceutical products. Net sales break down by family of products as follows: - pharmaceutical and OTC products (64.4%): for the treatment of viral infections, cardiovascular, dermatological, gynecological diseases, etc.; - medicines for rare diseases (35.6%). Net sales are distributed geographically as follows: Italy (14.3%), Europe (56.1%), America (20.4%), Asia and Oceania (6.7%) and Africa (2.5%).

Employees

4,539

Sector

Pharmaceuticals

Calendar

Feb. 18 - Q4 2025 Earnings Release (Projected)

More about the company